JP2007526285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007526285A5 JP2007526285A5 JP2007501295A JP2007501295A JP2007526285A5 JP 2007526285 A5 JP2007526285 A5 JP 2007526285A5 JP 2007501295 A JP2007501295 A JP 2007501295A JP 2007501295 A JP2007501295 A JP 2007501295A JP 2007526285 A5 JP2007526285 A5 JP 2007526285A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- pyrimidin
- triazolo
- phenylbutyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2- Isopropyl-4,5,6,7-tetrahydropyrazolo [1,5-a] pyridin-3-yl Chemical group 0.000 claims 7
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 claims 4
- 208000014644 Brain disease Diseases 0.000 claims 3
- 208000032274 Encephalopathy Diseases 0.000 claims 3
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 claims 3
- FBCDRHDULQYRTB-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;trihydrate;hydrochloride Chemical compound O.O.O.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 FBCDRHDULQYRTB-UHFFFAOYSA-N 0.000 claims 2
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 claims 2
- CCXIVOGMSQZBSB-UHFFFAOYSA-N [5-(1-benzyl-6-fluoroindazol-3-yl)furan-2-yl]methanol Chemical compound O1C(CO)=CC=C1C(C1=CC=C(F)C=C11)=NN1CC1=CC=CC=C1 CCXIVOGMSQZBSB-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229960000835 tadalafil Drugs 0.000 claims 2
- 229960002381 vardenafil Drugs 0.000 claims 2
- GODZWYONGRENHA-UHFFFAOYSA-N 1-cyclopentyl-3-methyl-6-pyridin-4-yl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=2N=C(C=3C=CN=CC=3)NC(=O)C=2C(C)=NN1C1CCCC1 GODZWYONGRENHA-UHFFFAOYSA-N 0.000 claims 1
- MFKZGAAAKCDLHM-UHFFFAOYSA-N 1-cyclopentyl-6-(3-ethoxypyridin-4-yl)-3-ethyl-5H-pyrazolo[3,4-d]pyrimidin-4-one Chemical compound CCOC1=CN=CC=C1C(N1)=NC(=O)C2=C1N(C1CCCC1)N=C2CC MFKZGAAAKCDLHM-UHFFFAOYSA-N 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- ZCBNNBZAPHAFLM-UHFFFAOYSA-N 2-(2-propoxyphenyl)-1,2,5,9-tetrahydropurin-6-one Chemical compound CCCOC1=CC=CC=C1C1N=C2N=CNC2C(=O)N1 ZCBNNBZAPHAFLM-UHFFFAOYSA-N 0.000 claims 1
- PQTJTRTXCNZDFT-UHFFFAOYSA-N 2-(2-propoxyphenyl)-3,7-dihydropurin-6-one Chemical compound CCCOC1=CC=CC=C1C(N1)=NC(=O)C2=C1N=CN2 PQTJTRTXCNZDFT-UHFFFAOYSA-N 0.000 claims 1
- NFWIUUMQOPCHNV-UHFFFAOYSA-N 2-(4-ethoxy-2-phenylcycloheptyl)-1h-imidazole Chemical compound C1C(OCC)CCCC(C=2NC=CN=2)C1C1=CC=CC=C1 NFWIUUMQOPCHNV-UHFFFAOYSA-N 0.000 claims 1
- JEMJAABFSYOLAP-UHFFFAOYSA-N 2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester Chemical compound C12=CC=NC(OCC=3N=CC=CN=3)=C2C(=O)N(CC=2C=C(C)N=CC=2)C(C(=O)OC)=C1C1=CC(OC)=C(OC)C(OC)=C1 JEMJAABFSYOLAP-UHFFFAOYSA-N 0.000 claims 1
- NOIHTGOGFDFCBN-UHFFFAOYSA-N 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1h-imidazo[5,1-f][1,2,4]triazin-4-one;dihydrochloride Chemical compound Cl.Cl.CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 NOIHTGOGFDFCBN-UHFFFAOYSA-N 0.000 claims 1
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- LNSWDTFYXQGHQZ-UHFFFAOYSA-N 2-imidazol-1-yl-6-methoxy-n-(2-methoxyethyl)quinazolin-4-amine Chemical compound N=1C2=CC=C(OC)C=C2C(NCCOC)=NC=1N1C=CN=C1 LNSWDTFYXQGHQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 1
- WYFCDXPLQWBYLV-UHFFFAOYSA-N 3-(5-phenylpentan-2-yl)-5-(pyridin-4-ylmethyl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CN=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 WYFCDXPLQWBYLV-UHFFFAOYSA-N 0.000 claims 1
- JHBGAOYCONJKBW-UHFFFAOYSA-N 3-(5-phenylpentan-2-yl)-5-[(4-phenylphenyl)methyl]-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CC(=CC=2)C=2C=CC=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 JHBGAOYCONJKBW-UHFFFAOYSA-N 0.000 claims 1
- YLEPRCOBSGOCCW-UHFFFAOYSA-N 3-ethyl-8-[[2-(morpholin-4-ylmethyl)phenyl]methylamino]-1h-imidazo[4,5-g]quinazoline-2-thione Chemical group C=12C=C3NC(=S)N(CC)C3=CC2=NC=NC=1NCC1=CC=CC=C1CN1CCOCC1 YLEPRCOBSGOCCW-UHFFFAOYSA-N 0.000 claims 1
- VDXZLVXFVYDBNH-UHFFFAOYSA-N 4-[(3-chloro-4-methoxyphenyl)methylamino]-1-(4-hydroxypiperidin-1-yl)phthalazine-6-carbonitrile Chemical compound C1=C(Cl)C(OC)=CC=C1CNC(C1=CC(=CC=C11)C#N)=NN=C1N1CCC(O)CC1 VDXZLVXFVYDBNH-UHFFFAOYSA-N 0.000 claims 1
- LNMMZMTWCOIELH-UHFFFAOYSA-N 4-methyl-5-pyridin-4-yl-1,3-thiazole-2-carboxamide Chemical compound N1=C(C(N)=O)SC(C=2C=CN=CC=2)=C1C LNMMZMTWCOIELH-UHFFFAOYSA-N 0.000 claims 1
- UYBVXOPUCHLFBB-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-ylmethyl)-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=C3OCOC3=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 UYBVXOPUCHLFBB-UHFFFAOYSA-N 0.000 claims 1
- MTWHVOZRKLKMPK-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-ylmethyl)-3-nonan-3-yl-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound C1=C2OCOC2=CC(CC2=NC3=C(C(N2)=O)N=NN3C(CC)CCCCCC)=C1 MTWHVOZRKLKMPK-UHFFFAOYSA-N 0.000 claims 1
- YRVSSAHNWIKBOO-UHFFFAOYSA-N 5-[(3,4-dichlorophenyl)methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=C(Cl)C(Cl)=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 YRVSSAHNWIKBOO-UHFFFAOYSA-N 0.000 claims 1
- MAFKHHASELEAOY-UHFFFAOYSA-N 5-[(4-aminophenyl)methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CC(N)=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 MAFKHHASELEAOY-UHFFFAOYSA-N 0.000 claims 1
- BLWMVGBZGHLKMW-UHFFFAOYSA-N 5-[(4-bromophenyl)methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CC(Br)=CC=2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 BLWMVGBZGHLKMW-UHFFFAOYSA-N 0.000 claims 1
- OUXVHTSANLRICR-UHFFFAOYSA-N 5-[(4-morpholin-4-ylsulfinylphenyl)methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CC(=CC=2)S(=O)N2CCOCC2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 OUXVHTSANLRICR-UHFFFAOYSA-N 0.000 claims 1
- ZWXLRFCLVBVPPN-UHFFFAOYSA-N 5-[[4-(4-methylpiperazin-1-yl)sulfonylphenyl]methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(CC=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)=N2)=O)=C2N1C(C)CCCC1=CC=CC=C1 ZWXLRFCLVBVPPN-UHFFFAOYSA-N 0.000 claims 1
- GSGHEAPRWZPGKU-UHFFFAOYSA-N 5-[hydroxy(phenyl)methyl]-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(=N2)C(O)C=3C=CC=CC=3)=O)=C2N1C(C)CCCC1=CC=CC=C1 GSGHEAPRWZPGKU-UHFFFAOYSA-N 0.000 claims 1
- AFEPFRFHBOPKGA-UHFFFAOYSA-N 5-benzoyl-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-7-one Chemical compound N1=NC(C(NC(=N2)C(=O)C=3C=CC=CC=3)=O)=C2N1C(C)CCCC1=CC=CC=C1 AFEPFRFHBOPKGA-UHFFFAOYSA-N 0.000 claims 1
- JVXOVCCTKADOOP-UHFFFAOYSA-N 9-bromo-2-(3-hydroxypropyloxy)-5-(3-pyridylmethyl)-4h-pyrido [3,2,1-jk]carbazole-4-one Chemical compound O=C1C(C=23)=CC(OCCCO)=CC=2C2=CC=C(Br)C=C2N3C=C1CC1=CC=CN=C1 JVXOVCCTKADOOP-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- 208000029812 Cerebral Small Vessel disease Diseases 0.000 claims 1
- 206010067466 Cerebral microangiopathy Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- ZJWGRSIAKWRRCG-UHFFFAOYSA-N N-methyl-4-[[7-oxo-3-(5-phenylpentan-2-yl)-6H-triazolo[4,5-d]pyrimidin-5-yl]methyl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1CC(NC1=O)=NC2=C1N=NN2C(C)CCCC1=CC=CC=C1 ZJWGRSIAKWRRCG-UHFFFAOYSA-N 0.000 claims 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- UVNXNSUKKOLFBM-UHFFFAOYSA-N imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=CSC2=NC=CN21 UVNXNSUKKOLFBM-UHFFFAOYSA-N 0.000 claims 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- SANFLTPRLLETKD-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-2-imidazol-1-yl-6-methylthieno[2,3-d]pyrimidin-4-amine Chemical compound N1=C2SC(C)=CC2=C(NCC=2C=C3OCOC3=CC=2)N=C1N1C=CN=C1 SANFLTPRLLETKD-UHFFFAOYSA-N 0.000 claims 1
- 125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 claims 1
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 229960003310 sildenafil Drugs 0.000 claims 1
- 229960002639 sildenafil citrate Drugs 0.000 claims 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- WTVSOESDARPVQO-UHFFFAOYSA-N triazolo[4,5-d]pyrimidin-7-one Chemical compound O=C1N=CN=C2N=NN=C12 WTVSOESDARPVQO-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 229960001540 vardenafil hydrochloride Drugs 0.000 claims 1
- 229960004573 vardenafil hydrochloride trihydrate Drugs 0.000 claims 1
- 230000004865 vascular response Effects 0.000 claims 1
- 229950005577 vesnarinone Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100909.3 | 2004-03-05 | ||
| EP04100909 | 2004-03-05 | ||
| PCT/EP2005/050958 WO2005089766A1 (en) | 2004-03-05 | 2005-03-03 | Novel use for pde5 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007526285A JP2007526285A (ja) | 2007-09-13 |
| JP2007526285A5 true JP2007526285A5 (enExample) | 2008-03-13 |
| JP4838792B2 JP4838792B2 (ja) | 2011-12-14 |
Family
ID=34928893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007501295A Expired - Fee Related JP4838792B2 (ja) | 2004-03-05 | 2005-03-03 | Ｐｄｅ５阻害剤のための新規の使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7666872B2 (enExample) |
| EP (1) | EP1740183B8 (enExample) |
| JP (1) | JP4838792B2 (enExample) |
| AT (1) | ATE445402T1 (enExample) |
| AU (1) | AU2005224043B2 (enExample) |
| CA (1) | CA2557792C (enExample) |
| DE (1) | DE602005017135D1 (enExample) |
| ES (1) | ES2334682T3 (enExample) |
| WO (1) | WO2005089766A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841300B2 (en) * | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체 |
| CN101754756A (zh) * | 2007-05-18 | 2010-06-23 | 维瓦斯公司 | 包含磷酸二酯酶-5抑制剂的新组合和它们的用途 |
| KR101002490B1 (ko) * | 2007-06-09 | 2010-12-17 | 동아제약주식회사 | 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물 |
| AU2012201640B2 (en) * | 2007-06-13 | 2014-09-04 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| AU2014213552B2 (en) * | 2007-06-13 | 2016-11-24 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| EP2282779B1 (en) * | 2008-04-29 | 2013-03-13 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| MX2011002060A (es) * | 2008-08-25 | 2011-04-05 | Irm Llc | Moduladores de la senda de hedgehog. |
| US8962770B2 (en) * | 2009-12-30 | 2015-02-24 | Sabic Global Technologies B.V. | Blends of isosorbide-based copolycarbonate, method of making, and articles formed therefrom |
| US8888802B2 (en) * | 2010-12-21 | 2014-11-18 | Alcon Research, Ltd. | Vitrectomy probe with adjustable cutter port size |
| EP2535049A1 (en) * | 2011-06-17 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Tadalafil for the treatment of dementia |
| AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| RU2497203C2 (ru) * | 2012-02-13 | 2013-10-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ фармакологической коррекции ишемии скелетной мышцы силденафилом, в том числе при l-name-индуцированном дефиците оксида азота |
| DK2961741T3 (en) * | 2013-03-01 | 2017-07-03 | Fund Para La Investig Medica Aplicada | Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| US10647791B2 (en) | 2018-03-30 | 2020-05-12 | Sekisui Chemical Co., Ltd. | Polyvinyl alcohol used as dispersing agents for polyvinyl chloride suspension polymerization, dispersing agents comprising the polyvinyl alcohol, and method for producing polyvinyl chloride using the polyvinyl alcohol |
| JP7770572B2 (ja) * | 2021-12-14 | 2025-11-14 | チェンアオ ジンインファ ファーマシューティカル | 虚血性脳損傷を予防または治療するための医薬の調製におけるアイルデナフィルまたはその塩の使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| DE69720542D1 (de) * | 1996-05-31 | 2003-05-08 | Mochida Pharm Co Ltd | PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN |
| AU6230098A (en) * | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| JPH10298164A (ja) * | 1997-02-27 | 1998-11-10 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体、その製法及びその合成中間体 |
| NZ517324A (en) | 1999-10-11 | 2003-09-26 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| ATE348618T1 (de) * | 2001-05-09 | 2007-01-15 | Bayer Healthcare Ag | Neue verwendung von 2-(2-ethoxy-5-(4-methyl- piperazin-1-sulfonyl)-phenyl)-5-methyl-7-propyl 3h-imidazo(5,1-f)(1,2,4)triazin-4-on |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| EP1461022A2 (en) | 2001-12-17 | 2004-09-29 | ALTANA Pharma AG | Use of selective pde5 inhibitors for treating partial and global respiratory failure |
-
2005
- 2005-03-03 EP EP05716901A patent/EP1740183B8/en not_active Expired - Lifetime
- 2005-03-03 US US10/590,992 patent/US7666872B2/en not_active Expired - Fee Related
- 2005-03-03 CA CA2557792A patent/CA2557792C/en not_active Expired - Fee Related
- 2005-03-03 DE DE602005017135T patent/DE602005017135D1/de not_active Expired - Lifetime
- 2005-03-03 WO PCT/EP2005/050958 patent/WO2005089766A1/en not_active Ceased
- 2005-03-03 JP JP2007501295A patent/JP4838792B2/ja not_active Expired - Fee Related
- 2005-03-03 AT AT05716901T patent/ATE445402T1/de not_active IP Right Cessation
- 2005-03-03 AU AU2005224043A patent/AU2005224043B2/en not_active Ceased
- 2005-03-03 ES ES05716901T patent/ES2334682T3/es not_active Expired - Lifetime
-
2010
- 2010-01-04 US US12/654,787 patent/US8278300B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007526285A5 (enExample) | ||
| JP2006528229A5 (enExample) | ||
| EP3875078A1 (en) | Compounds for the treatment of covid-19 | |
| RU2431635C2 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| RU2424242C2 (ru) | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| JP2022184886A5 (enExample) | ||
| Cherukupalli et al. | An appraisal on synthetic and pharmaceutical perspectives of pyrazolo [4, 3-d] pyrimidine scaffold | |
| US8278300B2 (en) | Use for PDE5 inhibitors | |
| ABDULLAH EL-ASSIERY et al. | Synthesis of some new annulated pyrazolo-pyrido (or pyrano) pyrimidine, pyrazolopyridine and pyranopyrazole derivatives | |
| JP2019535664A5 (enExample) | ||
| HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
| US20120178915A1 (en) | Pyrimidine derivatives and analogs, preparation method and use thereof | |
| JPWO2020005873A5 (enExample) | ||
| JP2005502683A5 (enExample) | ||
| JPWO2020005877A5 (enExample) | ||
| HRP20140232T1 (hr) | Novi derivati fenilimidazola kao inhibitori enzima pde10a | |
| CA2529007A1 (en) | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases | |
| JP2006511491A5 (enExample) | ||
| HRP20121022T1 (hr) | Kondenzirani bicikliäśki pirimidini | |
| HRP20211483T1 (hr) | Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka | |
| JP2016537384A5 (enExample) | ||
| JPWO2020231977A5 (enExample) | ||
| JP2013518823A5 (enExample) | ||
| US20240156825A1 (en) | Use of selective vegfr2 and fgfr1 inhibitors | |
| RU2007102847A (ru) | Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора dev |